• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Why are there so many problems between the BRM's and RAM's/NAM's?





Why are infusion centers still complaining about losses related to infusion of Tysabri? Is'nt this something that we can control? Price increases, discounts to wholesalers, managed care etc all combine to determine available margin to the clinician. What's happening?
 












managed markets is the place to be folks. Make up account calls and blame sales for poor performance! Tier 3, so what, learn to sell against it! Shifting blame is the best thing these folks do! 5 office days a week!